I-BET-151 | Interleukin Related interleukin-related.com

Product Name :
I-BET-151

Search keywords :
I-BET151

drugId :
null

Target Vo:
Bromodomain and extra terminal domain protein

Target Vo Short Name :
BET

Moa_Name:
Bromodomain and extra terminal domain protein inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Glaxosmithkline Plc

Active Company_Name :
Glaxosmithkline Plc

Active Indication_Name:
Sepsis

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
cIAP2 (YP5071) Mouse mAb supplier
Oleclumab MedChemExpress
CDC23 Antibody: CDC23 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 69 kDa, targeting to CDC23. It can be used for WB,ICC/IF assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts